InVivid (IVVD) Q3 2025: $87M Capital Infusion Powers Pivotal Antibody Launch Path
InVivid’s third quarter marked a strategic inflection, with a fresh $87 million capital raise positioning the company to accelerate pivotal studies and commercial expansion for its next-generation COVID antibody, VYD2311. The company’s Pemgarda franchise continued to scale, but leadership’s focus is squarely on leveraging regulatory momentum and clinical trial design to challenge the mRNA vaccine paradigm. With top-line data expected mid-2026 and a robust cash position, InVivid is executing a dual-front strategy of near-term revenue growth and long-term market disruption.
Summary
- Capital Raise Secures Clinical Execution: Recent $87 million funding enables pivotal VYD2311 trials and commercial scale-up.
- Regulatory and Clinical Differentiation: Upcoming Declaration and Liberty studies aim to directly address vaccine efficacy and safety gaps.
- Commercial Foundation Expands: Pemgarda’s momentum builds a launchpad for next-gen antibody adoption.
Business Overview
InVivid is a clinical-stage biotechnology company focused on infectious disease prevention through monoclonal antibodies, a class of lab-produced molecules that mimic immune defense. The company generates revenue via Pemgarda, its infused COVID antibody therapy for immunocompromised patients, and is advancing VYD2311, a next-generation, potentially vaccine-replacing antibody for broader populations. Its business model combines near-term specialty drug commercialization with long-cycle, high-impact R&D and regulatory advancement for broader indications.
Performance Analysis
Pemgarda revenues rose 41% year-over-year and 11% sequentially, reflecting increasing market penetration and successful contracting with over 15,000 group purchasing organization (GPO) sites. The company’s commercial reach now includes more than 1,200 infusion centers, with a strong reorder rate of 76%, signaling sticky demand among providers serving immunocompromised patients.
Financially, the $87 million capital raise—sourced from both a public offering and an at-the-market (ATM) facility—has significantly strengthened InVivid’s balance sheet. Management asserts the company is now funded through anticipated pivotal data in mid-2026, with runway potentially extending further if Pemgarda’s growth and cost discipline persist.
- Commercial Penetration Deepens: GPO and infusion site expansion underpins Pemgarda’s revenue climb, establishing a scalable infrastructure for future launches.
- Cash Position Fortified: The capital raise provides operational and clinical flexibility, reducing near-term financing risk.
- Operational Discipline Maintained: Leadership continues to stress cost control even as commercial and R&D investments ramp.
The quarter’s results reinforce InVivid’s ability to execute on both commercial and capital fronts, while setting the stage for a transformative product cycle with VYD2311.
Executive Commentary
"The third quarter for InVivid marked a turning point in our company's history and, we hope, also marked the beginning of substantial change in how we may prevent COVID for vulnerable Americans in the near future."
Mark Alia, Chief Executive Officer
"InVivid is now well capitalized through anticipated pivotal data of EYD 2311 in mid-2026, and depending upon continued PEMGRADA growth and continued operational discipline, potentially well beyond."
Bill Duke, Chief Financial Officer
Strategic Positioning
1. Pivotal Program Acceleration
FDA feedback on VYD2311 enabled InVivid to finalize the design of its Declaration and Liberty studies, both of which are intended to address shortcomings of current COVID vaccine data. The company is leveraging this regulatory clarity to move quickly, with pivotal trials set to launch around year-end and top-line data expected by mid-2026.
2. Commercial Infrastructure Readiness
Pemgarda’s expanding footprint in GPOs and infusion centers provides a ready-made channel for future VYD2311 adoption. The commercial team is also investing in digital engagement and field expansion to reach broader provider segments as the product profile shifts from infusion to intramuscular delivery.
3. Regulatory and Clinical Differentiation
Declaration and Liberty studies are designed to produce robust, placebo-controlled data on efficacy and safety, directly responding to gaps in long-term COVID vaccine data. Liberty’s head-to-head safety comparison with mRNA vaccines targets the primary barrier to vaccine uptake: safety concerns.
4. Pipeline and Platform Leverage
Early-stage discovery programs in RSV and measles highlight InVivid’s ambition to build a multi-pathogen antibody platform. The company aims to differentiate through resistance profiles and molecular properties, with updates on candidate nomination expected by year-end.
Key Considerations
This quarter’s developments reflect a company in transition, balancing commercial execution with high-stakes clinical and regulatory bets. The following considerations will shape InVivid’s trajectory:
- Market Expansion Potential: If VYD2311 meets clinical and regulatory hurdles, the addressable market could shift from a niche immunocompromised segment to a broad population-level opportunity.
- Safety and Efficacy Messaging: The Liberty study’s head-to-head design positions InVivid to capitalize on persistent vaccine hesitancy tied to side effect concerns.
- Commercial Channel Evolution: Transitioning from infusion-based delivery to intramuscular administration will require new provider education and patient access strategies.
- Pipeline Optionality: Progress in RSV and measles programs could unlock additional revenue streams and de-risk reliance on COVID franchise alone.
Risks
Clinical and regulatory timelines remain a key risk, as delays or negative data from the Declaration or Liberty studies could undermine the company’s core growth thesis. Commercial execution risk is elevated as the company transitions from specialty infusion to broader provider and patient populations. Additionally, competitive dynamics in the COVID prevention market—including evolving vaccine recommendations and potential new entrants—could pressure pricing and uptake. Management’s optimism is clear, but the path to broad adoption is not without hurdles.
Forward Outlook
For Q4 2025, InVivid expects:
- Initiation of Declaration and Liberty pivotal studies for VYD2311.
- Continued sequential growth in Pemgarda revenue and commercial footprint.
For full-year 2025, management maintains its focus on:
- Sustained Pemgarda growth and operating discipline.
- Progress toward VYD2311 pivotal data in mid-2026.
Leadership emphasized that the next 12 to 18 months are pivotal, with clinical data and regulatory milestones expected to drive significant value inflection. Commercial investments will scale in parallel with trial execution.
- Clinical trial initiation and execution pace.
- Commercial channel readiness for VYD2311 launch.
Takeaways
InVivid’s Q3 2025 results reinforce a dual-track growth story: near-term specialty revenue expansion and a high-conviction bet on redefining COVID prevention through antibody therapies.
- Capital Base Now Matches Ambition: The $87 million raise provides the firepower to execute pivotal trials without near-term dilution or financing overhang.
- Clinical and Regulatory Strategy Is Aggressive: Directly targeting vaccine limitations, InVivid seeks to position VYD2311 as a safer, more durable alternative.
- Execution on Commercial and R&D Fronts Will Be Scrutinized: Investors should watch for trial enrollment, regulatory clarity, and commercial channel evolution as leading indicators of future value creation.
Conclusion
InVivid exits Q3 2025 with momentum on both commercial and clinical fronts, a strengthened balance sheet, and a clear plan to challenge the COVID vaccine status quo. The coming year will test the company’s ability to deliver on its pivotal studies and scale its commercial infrastructure for a potentially transformative launch.
Industry Read-Through
InVivid’s approach signals a new phase in infectious disease prevention, where monoclonal antibodies could move from niche, high-risk populations to mainstream prophylaxis. The company’s focus on robust, placebo-controlled data and head-to-head safety studies directly addresses the credibility gap facing mRNA vaccines and highlights a broader industry push for differentiated, durable solutions. For biotechs and pharma peers, the bar for regulatory approval and commercial adoption is rising, with patient safety and real-world durability now central to market access. Companies with scalable antibody platforms and strong commercial execution will be best positioned to capture share as the COVID prevention market evolves and expands beyond its pandemic roots.